glycerin 200 MG/ML / lidocaine 43 MG/ML Medicated Pad

RxCUI
1602013
RxNorm name
glycerin 200 MG/ML / lidocaine 43 MG/ML Medicated Pad
Display name
Glycerin/Lidocaine (Topical)
Full name
glycerin 200 MG/ML / lidocaine 43 MG/ML Medicated Pad
Term type
SCD
Status
Active
Strength
20-4.3%
Dose form
Medicated Pad
Route
Topical
Updated
2026-10-17 23:57:30

RxNorm Status History#

Status
Active
Source
RXNORM
Current
YES
Release start
032015
Active start
032015
Multiple ingredient
YES
Branded
NO

Ingredients And Strength#

Ingredient, Strength, Base table
IngredientStrengthBaseBasis of strength
glycerin200 MG / 1 MLglyceringlycerin
lidocaine43 MG / 1 MLlidocainelidocaine

Dose Form Concepts#

Dose form, RxCUI table
Dose formRxCUI
Medicated Pad797271

Derived Ingredient Concepts#

Ingredient, RxCUI table
IngredientRxCUI
glycerin4910
lidocaine6387

Source Vocabulary Codes#

Code type, Values, Count table
Code typeValuesCountCategory
PRESCRIBABLEY1ATTRIBUTES
RXNAV_STRglycerin 200 MG/ML / lidocaine 43 MG/ML Medicated Pad1NAMES
RxNorm Nameglycerin 200 MG/ML / lidocaine 43 MG/ML Medicated Pad1NAMES
RxNorm Synonym
2 linked values
2NAMES
TTYSCD1ATTRIBUTES
RxCUI16020131CODES

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RECTICARELIDOCAINE AND GLYCERINFerndale Laboratories, Inc.2b94136a-4975-2925-e054-00144ff88e882024-12-17WarningsExact identifier
rxcui: 1602013

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
2b94136a-4975-2925-e054-00144ff88e88lidocaine HCl 5 % / glycerin 20 % Medicated Pad [PSN] · glycerin 200 MG/ML / lidocaine 43 MG/ML Medicated Pad [SCD] · glycerin 20 % / lidocaine 4.3 % (as lidocaine HCl 5 % ) Medicated Pad [SY] · glycerin 20 % / lidocaine HCl 5 % Medicated Pad [SY]43RectiCare Medicated Anorectal Wipes20241217

Drug Classes#

Source, Class ID, Class table
SourceClass IDClassTypeRelationshipDrug concept
ATCN01BBAmidesATC1-4lidocaine
ATCS02DAAnalgesics and anestheticsATC1-4lidocaine
ATCD04ABAnesthetics for topical useATC1-4lidocaine
ATCR02ADAnesthetics, localATC1-4lidocaine
ATCC01BBAntiarrhythmics, class IbATC1-4lidocaine
ATCA06AGEnemasATC1-4glycerin
ATCS01HALocal anestheticsATC1-4lidocaine
ATCC05ADLocal anestheticsATC1-4lidocaine
ATCA06AXOther drugs for constipationATC1-4glycerin
FDASPLD000485AllergensCHEMhas_chemical_structureglycerin
FDASPLD005990GlycerolCHEMhas_chemical_structureglycerin
FDASPLN0000175682Amide Local AnestheticEPChas_epclidocaine
FDASPLN0000175426AntiarrhythmicEPChas_epclidocaine
FDASPLN0000185370Non-Standardized Chemical AllergenEPChas_epcglycerin
FDASPLN0000184306Cell-mediated ImmunityPEhas_peglycerin
FDASPLN0000175629Increased Histamine ReleasePEhas_peglycerin
FDASPLN0000185001Increased IgG ProductionPEhas_peglycerin
FDASPLN0000175976Local AnesthesiaPEhas_pelidocaine
MEDRTD005990GlycerolCHEMhas_ingredientglycerin
MEDRTD008012LidocaineCHEMhas_ingredientlidocaine
MEDRTD000219Adams-Stokes SyndromeDISEASEci_withlidocaine
MEDRTD002056BurnsDISEASEmay_treatlidocaine
MEDRTD003248ConstipationDISEASEmay_treatglycerin
MEDRTD003872DermatitisDISEASEmay_treatglycerin
MEDRTD003872DermatitisDISEASEmay_preventglycerin
MEDRTD004342Drug HypersensitivityDISEASEci_withlidocaine
MEDRTD004342Drug HypersensitivityDISEASEci_withglycerin
MEDRTD064420Drug-Related Side Effects and Adverse ReactionsDISEASEmay_treatlidocaine
MEDRTD004935Esophageal DiseasesDISEASEmay_treatlidocaine
MEDRTD006967HypersensitivityDISEASEci_withlidocaine
MEDRTD009059Mouth DiseasesDISEASEmay_treatlidocaine
MEDRTD010146PainDISEASEmay_treatlidocaine
MEDRTD010146PainDISEASEmay_preventlidocaine
MEDRTD013614Tachycardia, ParoxysmalDISEASEmay_treatlidocaine
MEDRTD017180Tachycardia, VentricularDISEASEmay_treatlidocaine
MEDRTD014693Ventricular FibrillationDISEASEmay_treatlidocaine
MEDRTD018879Ventricular Premature ComplexesDISEASEmay_treatlidocaine
MEDRTN0000000180Sodium Channel InteractionsMOAhas_moalidocaine
MEDRTN0000000075Stool Bulking ActivityMOAhas_moaglycerin
MEDRTN0000008330Cardiac Rhythm AlterationPEhas_pelidocaine
MEDRTN0000008472Decreased Cardiac Muscle Organized Electrical ActivityPEhas_pelidocaine
MEDRTN0000008889Decreased Sensory-Somatic Nervous System Organized Electrical ActivityPEhas_pelidocaine
MEDRTN0000009035Emollient ActivityPEhas_peglycerin
MEDRTN0000009371Increased Large Intestinal MotilityPEhas_peglycerin
MEDRTN0000175976Local AnesthesiaPEhas_pelidocaine
MEDRTN0000009870Stimulation Large Intestine Fluid/Electrolyte AbsorptionPEhas_peglycerin

Properties#

Category, Property, Value table
CategoryPropertyValue
ATTRIBUTESAVAILABLE_STRENGTH200 MG/ML / 43 MG/ML
ATTRIBUTESGENERAL_CARDINALITYMULTI
ATTRIBUTESHUMAN_DRUGUS
ATTRIBUTESRXNAV_HUMAN_DRUGUS
NAMESPrescribable Synonymlidocaine HCl 5 % / glycerin 20 % Medicated Pad
SOURCESSourceNational Drug Data File Plus Source Vocabulary